Ose Pharma gets clinical milestone for IL7...Ose Immunotherapeutics has got the first milestone payment within its €272m deal with Servier inked in 2016. more ➔
How stroma cells trigger tumour angiogenes...Analyses of the stroma cell proteome have revealed how intratumoral hypoxia triggers the formation of dysfunctional blood vessels that block drugs from entering the tumour and push metastasis. … more ➔
Jennewein Biotechnologie expands into Chin...Jennewein Biotechnologie and Asia’s largest dairy company Yili Group have joined forces to develop an innovative infant formula tailored to the Chinese market. more ➔
Medicxi put €40m into two Sosei spin off...Sosei Group Corporation has spun out two programmes of its neurology pipeline into two newly created companies funded by venture fund Medicxi. more ➔
EMA greenlights two orphan drugs and two b...EMAs human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting. more ➔
Hitachi expands European reach in cell and...Hitachi Chemical Co. Ltd. is set to takeover cell and gene therapy CDMO apceth Biopharma GmbH to get a foothold in Europe, the second largest market for advanced therapies after the US. more ➔
Dewpoint Therapeutics kicks off with $60m...Dewpoint Therapeutics has attracted interested of investors with a completely new approach that might cure a huge array of devasting diseases. more ➔
IPO: Marinomed sets offer priceMarinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of €75 per new share. more ➔
Novozymes partners with Carbios subsidiary...Novozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020. more ➔
Biomarker predicts response to TNF blocker...A new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy. more ➔
